Investigations: Hb 11 5 g/100 ml, WBC 12,000 (normal differential), platelets 436,000, ESR 55 mm in I h (Westergren). Antistreptolysin-O titre normal. No Management: A six-week trial course of azathioprine and prednisolone produced no improvement in proteinuria. The development of a raised blood pressure required treatment with methyldopa. Since January 1970, the patient has remained free of cedema and normotensive on frusemide, spironolactone and methyldopa without significance change in glomerular function.
Further investigations of the complement system: The following abnormalities have been described in this patient: (1) Persistent hypocomplementemia with low C3. (2) Presence of breakdown products of C3 in plasma. (3) The patient's serum, when incubated with normal human serum, produced breakdown of C3 of the normal serum. (4) Metabolic studies using radiolabelled C3 suggest impaired C3 synthesis. These findings suggest that the reduction in serum C3 level is the result of a complex process involving both complement activation and depression of C3 synthesis. The presence of the so-called C3 nephritic factor (C3NeF) in the sera of patients with membranoproliferative glomerulonephritis, which can break down C3 when incubated with normal human serum, has been reported previously (Spitzer et al. 1969 ). C3NeF i; without effect on highly purified C3 and C3NeF requires some cofactor(s), present in normal human serum.
C3NeF has not been detected in all patients with membranoproliferative glomerulonephritis but when present it is closely associated with low serum levels of C3 (D K Peters, A Martin, A Weinstein, T M Barratt, J S Cameron & P J Lachmann, 1972, personal communication). The origin and nature of C3NeF are unknown but it has been detected in the anephric subject (Vallota etal. 1971) .
The recent demonstration of an alternative pathway for the activation of C3 (Gotze & Muller-Eberhard 1971) bypassing the early components Cl, C4 and C2, suggests that C3NeF and its cofactor(s) may act through such a system. The part played by C3NeF in membranoproliferative glomerulonephritis is unknown. It could be pathogenic, producing complementmediated damage, or protective by removing C3. Diminished synthesis of C3 in membranoproliferative glomerulonephritis was demonstrated by Alper & Rosen (1967) using radiolabelled C3, but Herdman et al. (1970) have shown increased breakdown in some patients. Diminished synthesis could be the result of a feedback mechanism resulting from C3 activation; this too may protect against complement-mediated tissue damage.
The association of lipodystrophy with various forms of glomerulonephritis, including the membranoproliferative form, has been reported previously (Jeune et al. 1965 , Lajouanine et al. 1968 , Hamza et al. 1970 . This is to be distinguished from any renal lesions associated with diabetes mellitus.
